Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Quantification of rare somatic single nucleotide variants by droplet digital PCR using SuperSelective primers

  • Pablo-Fontecha, Verónica|||0000-0001-9084-4597
  • Hernández-Illán, Eva
  • Reparaz, Andrea
  • Asensio, Elena
  • Morata, Jordi|||0000-0002-6146-4322
  • Tonda, Raúl
  • Lahoz, Sara|||0000-0002-4491-9911
  • Parra, Carolina
  • Lozano, Juan José
  • García-Heredia, Anabel
  • Martínez-Roca, Alejandro
  • Beltran i Agulló, Sergi|||0000-0002-2810-3445
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Jover, Rodrigo
  • Castells, Antoni|||0000-0001-8431-2033
  • Trullàs, Ramon
  • Podlesniy, Petar
  • Camps, Jordi|||0000-0003-2929-4228
Somatic single-nucleotide variants (SNVs) occur every time a cell divides, appearing even in healthy tissues at low frequencies. These mutations may accumulate as neutral variants during aging, or eventually, promote the development of neoplasia. Here, we present the SP-ddPCR, a droplet digital PCR (ddPCR) based approach that utilizes customized SuperSelective primers aiming at quantifying the proportion of rare SNVs. For that purpose, we selected five potentially pathogenic variants identified by whole-exome sequencing (WES) occurring at low variant allele frequency (VAF) in at-risk colon healthy mucosa of patients diagnosed with colorectal cancer or advanced adenoma. Additionally, two APC SNVs detected in two cancer lesions were added to the study for WES-VAF validation. SuperSelective primers were designed to quantify SNVs at low VAFs both in silico and in clinical samples. In addition to the two APC SNVs in colonic lesions, SP-ddPCR confirmed the presence of three out of five selected SNVs in the normal colonic mucosa with allelic frequencies ≤ 5%. Moreover, SP-ddPCR showed the presence of two potentially pathogenic variants in the distal normal mucosa of patients with colorectal carcinoma. In summary, SP-ddPCR offers a rapid and feasible methodology to validate next-generation sequencing data and accurately quantify rare SNVs, thus providing a potential tool for diagnosis and stratification of at-risk patients based on their mutational profiling.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications

  • Franch-Expósito, Sebastià|||0000-0002-4542-1701
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Vila-Casadesús, Maria|||0000-0001-6597-7953
  • Hernández-Illán, Eva
  • Esteban-Fabró, Roger
  • Díaz-Gay, Marcos|||0000-0003-0658-0467
  • Lozano, Juan José
  • Castells, Antoni|||0000-0001-8431-2033
  • Llovet, Josep Maria
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Camps Polo, Jordi|||0000-0003-2929-4228
Somatic copy number alterations (CNAs) are a hallmark of cancer, but their role in tumorigenesis and clinical relevance remain largely unclear. Here, we developed CNApp, a web-based tool that allows a comprehensive exploration of CNAs by using purity-corrected segmented data from multiple genomic platforms. CNApp generates genome-wide profiles, computes CNA scores for broad, focal and global CNA burdens, and uses machine learning-based predictions to classify samples. We applied CNApp to the TCGA pan-cancer dataset of 10,635 genomes showing that CNAs classify cancer types according to their tissue-of-origin, and that each cancer type shows specific ranges of broad and focal CNA scores. Moreover, CNApp reproduces recurrent CNAs in hepatocellular carcinoma and predicts colon cancer molecular subtypes and microsatellite instability based on broad CNA scores and discrete genomic imbalances. In summary, CNApp facilitates CNA-driven research by providing a unique framework to identify relevant clinical implications. CNApp is hosted at . In most cases, human cells contain two copies of each of their genes, yet sometimes this can change, an effect called copy number alteration (CNA). Cancer is a genetic disease and thus, studying the DNA from tumor samples is crucial to improving diagnosis and choosing the right treatment. Most tumors contain cells with CNAs; however, the impact of CNAs in cancer progression is poorly understood. CNAs can be studied by examining the genome of tumor cells and finding which regions display an unusual number of copies. It may also be possible to gather information about different cancer types by analyzing the CNAs in a tumor, but this approach requires the analysis of large amounts of data. To aid the analysis of CNAs in cancer cells, Franch-Expósito, Bassaganyas et al. have created an online tool called CNApp, which is able to identify and count CNAs in genomic data and link them to features associated with different cancers. The hope is that a better understanding of the effect of CNAs in cancer could help better diagnose cancers, and improve outcomes for patients. Potentially, this could also predict what type of treatment would work better for a specific tumor. Besides, by using a machine-learning approach, the tool can also make predictions about specific cancer subtypes in order to facilitate clinical decisions. Franch-Expósito, Bassaganyas et al. tested CNApp using previously existing cancer data from 33 different cancer types to show how CNApp can help the interpretation of CNAs in cancer. Moreover, CNApp can also use CNAs to identify different types of bowel (colorectal) cancer in a way that could help doctors to make decisions about treatment. Together these findings show that CNApp provides an adaptable and accessible research tool for the study of cancer genomics, which could provide opportunities to inform medical procedures.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Complete loss of epcam immunoexpression identifies epcam deletion carriers in msh2negative colorectal neoplasia

  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Gorostiaga, Iñigo|||0000-0003-0359-9963
  • Riera, Cristina|||0000-0002-3522-5598
  • Saperas, Esteban
  • Llort, Gemma|||0000-0001-9987-7862
  • Costa, Irmgard|||0000-0001-5760-8293
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Carrato, Cristina|||0000-0002-1953-8287
  • Navarro, Matilde Y.
  • Pineda, Marta|||0000-0002-5403-5845
  • Dueñas Cid, Nuria|||0000-0001-6624-3265
  • Brunet, Joan|||0000-0003-1945-3512
  • Marco-Molina, Vicente
  • Trias, Isabel|||0000-0001-9841-4380
  • Busteros-Moraza, José Ignacio
  • Mateu, Gemma
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Fernández-Figueras, Maria Teresa|||0000-0002-2366-7110
  • Esteller, M.|||0000-0003-4490-6093
  • Musulén, Eva|||0000-0002-9667-6464
The use of epithelial cell adhesion molecule (EPCAM) immunohistochemistry (IHC) is not included in the colorectal cancer (CRC) screening algorithm to detect Lynch syndrome (LS) patients. The aim of the present study was to demonstrate that EPCAM IHC is a useful tool to guide the LS germ-line analysis when a loss of MSH2 expression was present. We retrospectively studied MSH2 and EPCAM IHC in a large series of 190 lesions composed of malignant neoplasms (102), precursor lesions of gastrointestinal (71) and extra-gastrointestinal origin (9), and benign neoplasms (8) from different organs of 71 patients suspicious of being LS due to MSH2 alterations. LS was confirmed in 68 patients, 53 with MSH2 mutations and 15 with EPCAM 3'-end deletions. Tissue microarrays were constructed with human normal tissues and their malignant counterparts to assist in the evaluation of EPCAM staining. Among 154 MSH2-negative lesions, 17 were EPCAM-negative, including 10 CRC and 7 colorectal polyps, and 5 of them showed only isolated negative glands. All lesions showing a lack of EPCAM expression belonged to patients with EPCAM 3'-end deletions. EPCAM IHC is a useful screening tool, with 100% specificity to identify LS patients due to EPCAM 3'-end deletions in MSH2-negative CRC and MSH2-negative colorectal polyps.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tetraploidy-associated genetic heterogeneity confers chemo-radiotherapy resistance to colorectal cancer cells

  • Galofré, Claudia|||0000-0003-4415-4987
  • Gönül Geyik, Öykü
  • Asensio, Elena
  • Wangsa, Darawalee
  • Hirsch, Daniela|||0000-0001-8883-922X
  • Parra, Carolina
  • Saez, Jordi|||0000-0003-4888-9323
  • Mollà, Meritxell|||0000-0001-6215-2251
  • Yüce, Zeynep
  • Castells, Antoni|||0000-0001-8431-2033
  • Ried, Thomas|||0000-0002-0767-6009
  • Camps Polo, Jordi|||0000-0003-2929-4228
Tetraploidy, or whole-genome duplication, is a common phenomenon in cancer and preludes chromosome instability, which strongly correlates with disease progression, metastasis, and treatment failure. Therefore, it is reasonable to hypothesize that tetraploidization confers multidrug resistance. Nevertheless, the contribution of whole-genome duplication to chemo-radiotherapy resistance remains unclear. Here, using isogenic diploid and near-tetraploid clones from three colorectal cancer cell lines and one non-transformed human epithelial cell line, we show a consistent growth impairment but a divergent tumorigenic potential of near-tetraploid cells. Next, we assessed the effects of first-line chemotherapeutic drugs, other commonly used agents and ionizing radiation, and found that whole-genome duplication promoted increased chemotherapy resistance and also conferred protection against irradiation. When testing the activation of apoptosis, we observed that tetraploid cells were less prone to caspase 3 activation after treatment with first-line chemotherapeutic agents. Furthermore, we found that pre-treatment with ataxia telangiectasia and Rad3 related (ATR) inhibitors, which targets response to replication stress, significantly enhanced the sensitivity of tetraploid cells to first-line chemotherapeutic agents as well as to ionizing radiation. Our findings provide further insight into how tetraploidy results in greater levels of tolerance to chemo-radiotherapeutic agents and, moreover, we show that ATR inhibitors can sensitize near-tetraploid cells to commonly used chemo-radiotherapy regimens.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Centrosome reduction in newly-generated tetraploid cancer cells obtained by separase depletion

  • Galofré, Claudia|||0000-0003-4415-4987
  • Asensio, Elena
  • Ubach, Maria
  • Torres, Irianna M.
  • Quintanilla, Isabel
  • Castells, Antoni|||0000-0001-8431-2033
  • Camps Polo, Jordi|||0000-0003-2929-4228
Tetraploidy, a common feature in cancer, results in the presence of extra centrosomes, which has been associated with chromosome instability (CIN) and aneuploidy. Deregulation in the number of centrosomes triggers tumorigenesis. However, how supernumerary centrosomes evolve during the emergence of tetraploid cells remains yet to be elucidated. Here, generating tetraploid isogenic clones in colorectal cancer and in non-transformed cells, we show that near-tetraploid clones exhibit a significant increase in the number of centrosomes. Moreover, we find that centrosome area in near-tetraploids is twice as large as in near-diploids. To evaluate whether centrosome clustering was occurring, we next analysed the number of centrioles revealing centriole amplification. Notwithstanding, more than half of the near-tetraploids maintained in culture do not present centrosome aberrations. To test whether cells progressively lost centrioles after becoming near-tetraploid, we transiently transfected diploid cells with siRNA against ESPL1 /Separase, a protease responsible for triggering anaphase, to generate newly near-tetraploid cells. Finally, using this model, we assessed the number of centrioles at different time-points after tetraploidization finding that near-tetraploids rapidly lose centrosomes over time. Taken together, these data demonstrate that although most cells reduce supernumerary centrosomes after tetraploidization, a small fraction retains extra centrioles, potentially resulting in CIN.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

PCIG, a web-based application to explore immune-genomics interactions across cancer types

  • Pedrola Gómez, Anna|||0000-0002-0490-3851
  • Franch-Expósito, Sebastià|||0000-0002-4542-1701
  • Lahoz, Sara|||0000-0002-4491-9911
  • Esteban-Fabró, Roger
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Camps Polo, Jordi|||0000-0003-2929-4228
Genomic alterations can modulate the tumor immunophenotype depending on their nature and tissue of origin. Although this immune-genomic interaction may shape disease progression and response to immunotherapy, the factors governing such dynamics and the influence of each tissue-specific context remain poorly understood. Here, we have developed the PanCancer ImmunoGenomics (PCIG) tool, a web-based resource that provides researchers with the opportunity to mine immunome-genome relationships across several cancer types using data from the Pan-Cancer Analysis of Whole-Genomes (PCAWG) study, which comprises.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Copy-number intratumor heterogeneity increases the risk of relapse in chemotherapy-naive stage colon cancer

  • Lahoz, Sara|||0000-0002-4491-9911
  • Archilla, Ivan|||0000-0002-2142-0608
  • Asensio, Elena
  • Hernández-Illán, Eva
  • Ferrer Menduiña, Queralt|||0000-0003-3177-4618
  • López-Prades, Sandra|||0000-0001-8208-2959
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Rey Azpiri, Javier del|||0000-0001-7887-7871
  • Sanz-Pamplona, Rebeca
  • Lozano, Juan José
  • Castells, Antoni|||0000-0001-8431-2033
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Camps Polo, Jordi|||0000-0003-2929-4228
Optimal selection of high-risk patients with stage II colon cancer is crucial to ensure clinical benefit of adjuvant chemotherapy. Here, we investigated the prognostic value of genomic intratumor heterogeneity and aneuploidy for disease recurrence. We combined targeted sequencing, SNP arrays, fluorescence in situ hybridization, and immunohistochemistry on a retrospective cohort of 84 untreated stage II colon cancer patients. We assessed the clonality of copy-number alterations (CNAs) and mutations, CD8 + lymphocyte infiltration, and their association with time to recurrence. Prognostic factors were included in machine learning analysis to evaluate their ability to predict individual relapse risk. Tumors from recurrent patients displayed a greater proportion of CNAs compared with non-recurrent (mean 31.3% versus 23%, respectively; p = 0.014). Furthermore, patients with elevated tumor CNA load exhibited a higher risk of recurrence compared with those with low levels [ p = 0.038; hazard ratio (HR) 2.46], which was confirmed in an independent cohort (p = 0.004; HR 3.82). Candidate chromosome-specific aberrations frequently observed in recurrent cases included gain of the chromosome arm 13q (p = 0.02; HR 2.67) and loss of heterozygosity at 17q22-q24.3 (p = 0.05; HR 2.69). CNA load positively correlated with intratumor heterogeneity (R = 0.52; p < 0.0001). Consistently, incremental subclonal CNAs were associated with an elevated risk of relapse (p = 0.028; HR 2.20), which we did not observe for subclonal single-nucleotide variants and small insertions and deletions. The clinico-genomic model rated an area under the curve of 0.83, achieving a 10% incremental gain compared with clinicopathological markers (p = 0.047). In conclusion, tumor aneuploidy and copy-number intratumor heterogeneity were predictive of poor outcome and improved discriminative performance in early-stage colon cancer. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cytology Smears, An Enhanced Alternative Method for Colorectal Cancer pN Stage-A Multicentre Study

  • Diaz-Mercedes, Sherley|||0000-0002-8164-8639
  • Archilla, Ivan|||0000-0002-2142-0608
  • Lahoz, Sara|||0000-0002-4491-9911
  • Rodrigo Calvo, María Teresa|||0000-0001-6675-3425
  • López-Prades, Sandra|||0000-0001-8208-2959
  • Tarragona, Jordi|||0000-0002-1459-4087
  • Landolfi, Stefania|||0000-0002-1059-635X
  • Concha, Angel
  • Machado, Isidro|||0000-0001-7318-1330
  • Maurel, Joan|||0000-0002-9413-5592
  • Chic, Nuria
  • Castells, Antoni|||0000-0001-8431-2033
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Camps Polo, Jordi|||0000-0003-2929-4228
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
Recurrence of stage II (pT3-T4 pN0) colorectal cancer (CRC) occurs in about 15% of patients and it is often due to undetected lymph node (LN) metastases with conventional pathology haematoxylin and eosin (H&E) LN analysis. Despite more sensitive molecular methods of LN staging having proved to have prognostic value in stage II CRC, we aimed at determining whether the pN stage could be better assessed with LN cytology smears. We analysed 3936 LNs from 217 CRC surgical resections, using three methods, H&E, cytology smears, and the One Step Nucleic Acid Amplification (OSNA) molecular assay. We compared the pN stages obtained from both H&E and cytology, as well as with the OSNA results. We concluded that LN analysis with cytology smears not only enables performing the pN stage, but detects more LN metastases than H&E, with a similar detection rate to molecular methods. Cytology LN analysis would allow a better patient therapeutic management. Stage II colorectal cancer (CRC) recurrence remains a clinical problem. Some of these patients are true stage III CRC with a pN0 pathology stage. This large prospective multicentre cohort study aimed at evaluating the diagnostic ability of lymph node (LN) cytology smears to perform the pN stage and compare it with the conventional haematoxylin and eosin (H&E) pathology pN stage. Additionally, we used the One-Step Nucleic Acid Amplification (OSNA), a high-sensitive molecular method of LN staging. A total of 3936 fresh LNs from 217 CRC surgical specimens were examined by three methods, H&E, LN cytology smears, and OSNA. H&E detected 29% of patients with positive LNs, cytology smears 35%, and OSNA 33.2% (p < 0.0001). H&E and cytology concordantly classified 92.2% of tumours, and 88.5% between OSNA and H&E. Cytology had 96.8% sensitivity and 90.3% specificity to discriminate positive/negative patients compared to H&E (p = 0.004), and 87.3% sensitivity and 89% specificity when compared to OSNA (p = 0.56). Patients with positive LNs detected by any of the three methods had significantly worse disease-free and overall survival. We conclude that pN stage accuracy for detecting positive LNs is superior with LN cytological smears than with conventional H&E, which would enable a better pN stage and management of early-stage CRC patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53 -Mutated Metastatic Colorectal Cancer

  • Lahoz, Sara|||0000-0002-4491-9911
  • Rodríguez, Adela|||0000-0002-4899-6607
  • Fernández Barat, Laia|||0000-0001-7528-9636
  • Gorría, Teresa
  • Moreno, Reinaldo
  • Esposito, Francis|||0000-0002-5028-9637
  • Oliveres, Helena|||0000-0003-1801-1181
  • Albiol, Santiago
  • Saurí Nadal, Tamara|||0000-0002-7479-5120
  • Pesantez, David|||0000-0003-0257-8538
  • Riu-Viladoms, G.|||0000-0002-8259-0811
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Jares, Pedro
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Pineda, Estela|||0000-0003-2128-747X
  • Castells, Antoni|||0000-0001-8431-2033
  • Prat, Aleix|||0000-0003-2377-540X
  • Maurel, Joan|||0000-0002-9413-5592
  • Camps Polo, Jordi|||0000-0003-2929-4228
The mutational status of certain genes can be useful to advance therapeutic decision making and clinical management of cancer patients. In metastatic colorectal cancer, current clinicopathological factors employed in clinical practice have low or modest individual effect on survival, leading to a poor ability to discriminate patients at high risk. Here, we obtained data from metastatic colorectal cancer patients undergoing molecular testing by targeted gene sequencing, and we identified SMAD4 and FBXW7 mutated genes as negative prognostic markers in TP53 -driven tumors, which also improved the predictive performance to discriminate high-risk patients beyond clinical factors alone. This negative prognostic impact of co-occurring SMAD4 / TP53 and FBXW7 / TP53 mutations was confirmed in an independent validation analysis using publicly available data. Next-generation sequencing (NGS) provides a molecular rationale to inform prognostic stratification and to guide personalized treatment in cancer patients. Here, we determined the prognostic and predictive value of actionable mutated genes in metastatic colorectal cancer (mCRC). Among a total of 294 mCRC tumors examined by targeted NGS, 200 of them derived from patients treated with first-line chemotherapy plus/minus monoclonal antibodies were included in prognostic analyses. Discriminative performance was assessed by time-dependent estimates of the area under the curve (AUC). The most recurrently mutated genes were TP53 (64%), KRAS or NRAS (49%), PIK3CA (15%), SMAD4 (14%), BRAF (13%), and FBXW7 (9.5%). Mutations in FBXW7 correlated with worse OS rates (p = 0.036; HR, 2.24) independently of clinical factors. Concurrent mutations in TP53 and FBXW7 were associated with increased risk of death (p = 0.02; HR, 3.31) as well as double-mutated TP53 and SMAD4 (p = 0.03; HR, 2.91). Analysis of the MSK-IMPACT mCRC cohort (N = 1095 patients) confirmed the same prognostic trend for the previously identified mutated genes. Addition of the mutational status of these genes upon clinical factors resulted in a time-dependent AUC of 87%. Gene set enrichment analysis revealed specific molecular pathways associated with SMAD4 and FBXW7 mutations in TP53 -defficient tumors. Conclusively, SMAD4 and FBXW7 mutations in TP53 -altered tumors were predictive of a negative prognostic outcome in mCRC patients treated with first-line regimens.